NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Has ‘Buy’ Rating Reiterated by Aegis Capital; Reaches Key Milestone in ZX008 Dravet Syndrome Phase 3 Program

Zogenix (NASDAQ: ZGNX) has been reiterated at a ‘Buy’ rating and $28 price target by Aegis Capital Corp. The company recently announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome, a key milestone in the company’s phase 3 program. The two-cohort study will assess the pharmacokinetic and safety profile of single doses of ZX008, clobazam and valproate when added to stiripentol, followed by an evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to a drug regimen that includes stiripentol, clobazam and valproate in a randomized, double-blind, placebo-controlled parallel group.

To learn more, visit

About Zogenix, Inc.

Zogenix is a pharmaceutical company committed to developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit

Please see full disclaimers on the NetworkNewsWire website:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s